

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CSPC PHARMACEUTICAL GROUP LIMITED

石藥集團有限公司

(Incorporated in Hong Kong with limited liability)

(Stock Code: 1093)

VOLUNTARY ANNOUNCEMENT

CPO301 RECEIVES FAST TRACK DESIGNATION FROM THE US FDA

The board of directors (the “**Board**”) of CSPC Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that CPO301, a first-in-class antibody drug conjugate (ADC) developed by the Group, has received Fast Track Designation from the US Food and Drug Administration (FDA) for the treatment of patients with recurrent or metastatic squamous non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) overexpression that has progressed on or after treatment with platinum-based chemotherapy and anti-PD-(L1) therapy.

Lung cancer is one of the leading causes of cancer incidence and mortality worldwide. Though many effective therapeutic treatments have been developed, there are still unmet medical needs for the effective treatment of recurrent or metastatic squamous NSCLC. CPO301 demonstrated encouraging efficacy and satisfactory safety and tolerability in recurrent or metastatic squamous NSCLC patients enrolled in the Phase I studies in China and the US.

This is the second Fast Track Designation granted by the US FDA for CPO301. The first Fast Track Designation was granted for the treatment of patients with metastatic NSCLC harbouring EGFR mutations who are relapsed/refractory to or ineligible for EGFR targeting therapy such as 3rd-generation EGFR inhibitors including Osimertinib. These designations shall expedite the development of CPO301 in the US.

By Order of the Board
CSPC Pharmaceutical Group Limited
CAI Dongchen
Chairman

Hong Kong, 8 October 2024

As at the date of this announcement, the Board comprises Mr. CAI Dongchen, Mr. ZHANG Cuilong, Mr. WANG Zhenguo, Mr. PAN Weidong, Mr. WANG Huaiyu, Dr. LI Chunlei, Dr. JIANG Hao, Dr. YAO Bing and Mr. CAI Xin as executive directors; and Mr. WANG Bo, Mr. CHEN Chuan, Prof. WANG Hongguang, Mr. AU Chun Kwok Alan, Mr. LAW Cheuk Kin Stephen and Ms. LI Quan as independent non-executive directors.